Assessing the Economic Value of Anticancer Therapies

@article{Neymark1998AssessingTE,
  title={Assessing the Economic Value of Anticancer Therapies},
  author={Niels Neymark},
  journal={Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer},
  year={1998},
  volume={148},
  pages={
          1-285
        }
}
  • N. Neymark
  • Published 17 July 1998
  • Medicine
  • Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Introduction.- Epidemiology of Cancer.- Cancer and Some Basics of the Main Treatment Modalities.- A Brief Introduction to Economic Evaluation.- The Economic Burden of Cancer.- Breast Cancer.- Lung Cancer.- Colorectal Cancer.- Prostate Cancer.- Genitourinary and Gynecological Cancer.- Haematological Malignancies.- Supportive Care I: Emesis and Infections.- Supportive Care II: Haematological Support.- Palliative Care.- Conclusion.- References.- 

Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)

TLDR
This review provides an overview of the available literature concerning the economics of treating non-small–cell lung cancer (NSCLC) and addresses the global costs of LCs.

Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium

TLDR
The present economic evaluation has shown that the substitution of paclitaxel for cyclophosphamide in the chemotherapy regimen for women with advanced ovarian cancer leads to a significant improvement in patient survival, which is associated with an increase in costs for the Belgian health insurance system.

Measuring economic outcomes of cancer.

TLDR
An introduction to the nature and measurement of economic outcomes in cancer is provided and the reader entry points to a considerable literature on measuring economic endpoints in health and medicine.

Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

TLDR
Based on the phase III FDA licensing trial, amifostine use is associated with a favorable cost-utility profile that is in the range associated with widely used cancer therapeutic and supportive care agents.

Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis

TLDR
An economic model to compare the costs of three alternative strategies for prostate cancer follow-up in Ireland—the European Association of Urology (EAU) guidelines, the National Institute of Health Care Excellence (NICE) guidelines and current practice and suggests potential for significant savings within the Irish health care system associated with implementation of alternative models of prostate cancer following-up care.

Statistical methodology of phase III cancer clinical trials: advances and future perspectives.

Investigating chemotherapy adverse events : incidence, costs and consequences

TLDR
The models developed demonstrate that rigorous, systematic consideration of the key costs and consequences of adverse events is possible, and provide a standard way to include adverse events in future models of chemotherapy cost-effectiveness.

Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review

TLDR
Current modelling assumptions may restrict the understanding of the true impact of adverse events on cost effectiveness of antineoplastic drugs, and understanding could be improved through consideration of the selection of adverse Events, dose modifications, multiple events and quality of life in cost-effectiveness studies.